Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings

Wall Street analysts forecast that Abbott (ABT) will report quarterly earnings of $1.30 per share in its upcoming release, pointing to a year-over-year increase of 7.4%. It is anticipated that revenues will amount to $11.41 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.That said, let's delve into the average estimates of some Abbott metrics that Wall Street analysts commonly model and monitor.The consensus among analysts is that 'Net sales- Nutrition' will reach $2.20 billion. The estimate suggests a change of +6.3% year over year.Analysts' assessment points toward 'Net sales- Medical Devices- Diabetes Care' reaching $2.04 billion. The estimate indicates a year-over-year change of +18.2%.Based on the collective assessment of analysts, 'Net sales- Diagnostics' should arrive at $2.31 billion. The estimate points to a change of -4.4% from the year-ago quarter.The average prediction of analysts places 'Net sales- Established Pharmaceuticals' at $1.53 billion. The estimate points to a change of +9% from the year-ago quarter.Analysts expect 'Net sales- Diagnostics- U.S.' to come in at $909.57 million. The estimate points to a change of -11.9% from the year-ago quarter.According to the collective judgment of analysts, 'Geographic Revenue- U.S.' should come in at $4.38 billion. The estimate indicates a year-over-year change of +4.3%.The collective assessment of analysts points to an estimated 'Geographic Revenue- International' of $7.02 billion. The estimate indicates a year-over-year change of +9.2%.It is projected by analysts that the 'Net sales- Nutrition- International' will reach $1.23 billion. The estimate suggests a change of +9.8% year over year.The consensus estimate for 'Net sales- Nutrition- U.S.' stands at $966.71 million. The estimate indicates a change of +1.8% from the prior-year quarter.The combined assessment of analysts suggests that 'Net sales- Diagnostics- International' will likely reach $1.40 billion. The estimate indicates a change of +1.3% from the prior-year quarter.Analysts forecast 'Net sales- Medical Devices- Rhythm Management- U.S.' to reach $325.63 million. The estimate suggests a change of +13.1% year over year.Analysts predict that the 'Net sales- Medical Devices- Rhythm Management- International' will reach $339.38 million. The estimate suggests a change of +9.8% year over year. View all Key Company Metrics for Abbott here>>> Shares of Abbott have demonstrated returns of +0.5% over the past month compared to the Zacks S&P 500 composite's +3.5% change. With a Zacks Rank #3 (Hold), ABT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks